Aluminium-containing vaccines and macrophagic myofasciitis
GACVS reviewed the data of the case-control study performed in France and concluded, in accordance with previous statements,5 that the persistence of aluminium-containing macrophages at the site of a previous vaccination is not associated with specific clinical symptoms or disease.
Conclusions on other vaccine safety issues that are regularly followed by GACVS, and particularly on hepatitis B vaccine and multiple sclerosis and hepatitis B vaccine and leukaemia, can be found on the GACVS web site developed by the WHO secretariat for open access by interested parties (http://www.who.int/vaccine_safety/en).